A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
Conditions: Advanced Solid Tumor; Unresectable Solid Tumor; Melanoma; Renal Cell Carcinoma; Sarcoma; Triple Negative Breast Cancer; Pancreatic Ductal Adenocarcinoma; Non-Small Cell Lung Cancer Squamous; Non-Small Cell Lung Cancer Non-squamous; Colorectal Cancer ; Gastric Cancer; Biliary Tract Cancer; Gallbladder Cancer; Cholangiocarcinoma; Uterine Cancer; Ovarian Cancer; Cervical Cancer; Basal Cell Carcinoma; Bladder Cancer; Merkel Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; Cutaneous Squ amous Cell Carcinoma Interventions: Drug: MDNA11 Monotherapy; Drug: MDNA11 in combination with checkpoint inhibitor Sponsor: Medicenna Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Bile Duct Cancer | Cancer | Cancer & Oncology | Carcinoma | Cholangiocarcinoma | Gastroenterology | Immunotherapy | Melanoma | Research | Sarcomas | Skin Cancer | Study